Detailed analysis of tumor growth and survival rate showed that the combination group (GE11-Lipo CD73 siRNA+ Lipo Dox) could efficiently increase the survival rate compared to Liposomal doxorubicin group (P < 0.001) (Fig. 7B). The gene discussed is NT5E; the disease is neoplasm.